NasdaqGM:STAAMedical Equipment
STAAR Surgical (STAA) Is Up 12.0% After FDA Expands EVO ICL Age Range to 60 – Has The Bull Case Changed?
In February 2026, STAAR Surgical announced that the FDA approved an expanded age indication for its EVO/EVO+ Visian Implantable Collamer Lenses, extending U.S. use from ages 21–45 to 21–60 following three-year safety data.
This broader label meaningfully enlarges the potential U.S. candidate pool for EVO ICL, especially among adults aged 46–60 who were previously excluded.
We’ll now examine how opening EVO ICL access to patients up to age 60 could reshape STAAR Surgical’s longer-term...